









#### **Outline**

1

• What is the problem?

2

• How are we going to solve the problem?

3

What are the barriers and opportunities?


• What is the problem?

#### ADRD economic costs: Current estimates and future projections

ADRD imposes a substantial economic burden on patients, caregivers, and the health care system

#### Total health care costs for ADRD (2019):

### \$290 billion



**DE GRUYTER** 

Forum for Health Economics and Policy 2014; aop

The Value of Delaying Alzheimer's Disease
Onset

**Year 2010** 

Year 2050 (status quo)



3.6M ADRD patients

9.1M ADRD patients




\$307B/yr


\$1.5T/yr

People with ADRD incur higher health care costs than those without the condition, even before they receive the diagnosis

#### Medicare costs of ADRD vs. non-ADRD




#### Medicare costs of ADRD vs. non-ADRD




## Comorbidities are highly prevalent in people with ADRD and substantially increase care costs

#### Comorbidities in Medicare beneficiaries with ADRD



## ADRD can complicate comorbidity management and increase care costs



# ADRD are associated with substantial caregiver "spillover" costs and health effects

#### **ADRD** caregiver burden

>18 billion hours of (unpaid) informal care,
 valued at \$234 billion (2019 AA Facts & Figures)

Increased risk of anxiety, depression, and sleep disorders



• What is the problem?




• How are we going to solve the problem?


# Bend the cost curve: Understand ADRD cost drivers

# Inpatient, nursing home and end-of-life care costs are high in ADRD

#### **ADRD** cost drivers



#### **ADRD** cost drivers



#### In 2013

410,000

**Medicare ADRD patients had** 

**Avoidable hospitalizations** 

**Unplanned readmissions** 

\$4.7B

### ADRD cost drivers differ by care setting

#### ADRD cost drivers differ by care setting

#### **Community-based**



40% direct costs
60% informal care costs

#### Institutionalized




>85% direct costs

Schaller et al. Int J Geriatr Psychiatry 2014

# ADRD costs rise with increasing disease severity

Annual AD costs, by disease stage




Gustavsson et al. A&D 2011; Green et al. A&D 2019

#### ADRD cost impact on stakeholders, by disease stage

	Preclinical Stage	Prodromal Stage	Mild Dementia	Moderate Dementia	Severe Dementia
Patients					
	ı				
-					

Jönsson, Lin, Khachaturian. A&D 2017

#### ADRD cost impact on stakeholders, by disease stage



#### **Treatment goals**

- Delay progression to more costly stages
- > Maintain functionality

Jönsson, Lin, Khachaturian. A&D 2017



• What is the problem?



How are we going to solve the problem?




What are the barriers and opportunities?


# Value of ADRD interventions & reimbursement challenges

# Intervention at earlier stages of ADRD may be more cost-effective

#### Cost-effectiveness of donepezil for mild/moderate AD



#### Disease spectrum



#### Will MCI therapy be cost-effective?





Alzheimer's & Dementia ■ (2019) 1-13

Featured Article

Assessing cost-effectiveness of early intervention in Alzheimer's disease: An open-source modeling framework

Colin Green<sup>a,\*</sup>, Ron Handels<sup>b,c</sup>, Anders Gustavsson<sup>c,d</sup>, Anders Wimo<sup>c</sup>, Bengt Winblad<sup>c,e</sup>, Anders Sköldunger<sup>c</sup>, Linus Jönsson<sup>c,f</sup>

#### Hypothetical, disease modifying treatment for MCI

Base case: \$51,000/QALY

#### Will MCI therapy be cost-effective?







Base case: \$51,000/QALY

Featured Article

Assessing cost-effectiveness of early intervention in Alzheimer's disease: An open-source modeling framework

Colin Green<sup>a, \*\*</sup>, Ron Handels<sup>b, c</sup>, Anders Gustavsson<sup>c, d</sup>, Anders Wimo<sup>c</sup>, Bengt Winblad<sup>c, c</sup>, Anders Sköldunger<sup>c</sup>, Linus Jönsson<sup>c, f</sup>

#### **Assumptions**

- Treatment cost: \$5,000/yr
- ➤ Treatment effectiveness: 20% reduction in MCI → AD conversion rate

#### For payers, the issue is budget impact

# Budget impact of an innovative agent \$84K


(Hepatitis C)



17,000 new cases/yr


\$1.4B/yr

### >130 AD treatment agents in clinical trial




Cost of care X # of people

**Duration of** disability



Source: Zaven Khachaturian

#### **Budget impact for AD?**






 $\frac{1}{2}$  of the AD

population

#### **Budget impact for AD: early intervention**



#### Are we prepared to meet demand?



Assessing the Preparedness of the U.S. Health Care System Infrastructure for an Alzheimer's Treatment

Jodi L. Liu, Jakub P. Hlávka, Richard Hillestad, Soeren Mattke

#### Are we prepared to meet demand?






people wboltese pasitive diotia apercialist terrosital wat idd see a dementia specialist to learn about treatment

14 months

dementia specialists in 2020

Wait times might be extensive



## Thank you!

plin@tuftsmedicalcenter.org

